You are here: Home » PF » News » Investments
;
Business Standard

Edelweiss's healthcare fund offers benefit of international diversification

Allocation to a thematic offering like the newly-launched healthcare index fund should, however, be limited

Topics
Edelweiss Group

Mumbai 

Edelweiss announces buy of JPMorgan India MF biz

Mutual Fund (AMC) has launched the MSCI India Domestic & World Healthcare 45 Index Fund. This is an open-end passive fund that will give Indian investors exposure to both domestic and global healthcare stocks. While many active funds focused on the pharma and healthcare segment are available in India, they invest in domestic stocks only.

The offering

This fund will have 70 per cent exposure to the domestic and 30 per cent to the international healthcare segment. In the domestic component, it will include the top 25 stocks based on market cap, covering sectors such as pharma, hospitals, diagnostics, life science and biotechnology.

On the global side, it will include 20 listed in the US belonging to four sub- sectors: pharma, healthcare, biotech and life sciences. "The fund provides investors with exposure to two themes that are not correlated with each other. The domestic component is a consumption growth story, while the international component is a research and innovation story. When you combine these two ideas together, you get a superior risk profile than you would from a pure domestic healthcare index," says Radhika Gupta, chief executive officer, Mutual Fund.

On the domestic side, the fund will give investors exposure to players in the domestic Indian pharma market (including subsidiaries of multinational focused on the Indian market). These players sell branded generic products in India, which gives this segment the characteristics of a consumer-oriented play. Two, investors will get exposure to large Indian pharma that are major players in the US and other developed markets, whether they have made a mark selling generics. Three, investors will get exposure to API (active pharmaceutical ingredients) manufacturers who supply to both Indian and global companies. And four, they will get exposure to hospitals and diagnostics centres.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.


We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, October 23 2020. 19:39 IST
RECOMMENDED FOR YOU